Apyx Medical Corporation (NASDAQ:APYX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seven brokerages that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $6.20.
A number of research firms have recently commented on APYX. Maxim Group initiated coverage on Apyx Medical in a report on Tuesday, September 29th. They set a “buy” rating and a $6.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apyx Medical in a research report on Monday, September 21st.
Get Our Latest Research Report on Apyx Medical
Institutional Investors Weigh In On Apyx Medical
Institutional investors have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC purchased a new position in shares of Apyx Medical in the 2nd quarter worth about $14,683,414. Sei Investments Co. lifted its stake in shares of Apyx Medical by 298.6% in the 1st quarter. Sei Investments Co. now owns 598,255 shares of the company’s stock valued at $2,208,000 after purchasing an additional 448,174 shares in the last quarter. BlackRock Inc. acquired a new position in shares of Apyx Medical in the 2nd quarter valued at about $2,519,000. AIGH Capital Management LLC acquired a new position in shares of Apyx Medical in the 2nd quarter valued at about $5,066,000. Finally, Kingsview Wealth Management LLC purchased a new stake in shares of Apyx Medical during the 2nd quarter worth about $962,000. Hedge funds and other institutional investors own 55.33% of the company’s stock.
Apyx Medical Stock Performance
Shares of APYX stock opened at $2.81 on Monday. The company has a debt-to-equity ratio of 3.54, a quick ratio of 3.85 and a current ratio of 4.95. The firm has a market capitalization of $118.37 million, a price-to-earnings ratio of -14.79 and a beta of 1.47. Apyx Medical has a one year low of $2.25 and a one year high of $5.08. The company has a 50 day moving average price of $2.72 and a 200 day moving average price of $3.55.
Apyx Medical (NASDAQ:APYX – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.05. The company had revenue of $14.03 million for the quarter, compared to analyst estimates of $13.29 million. Apyx Medical had a negative net margin of 14.16% and a negative return on equity of 68.79%. Sell-side analysts anticipate that Apyx Medical will post -0.21 EPS for the current year.
Apyx Medical Company Profile
Apyx Medical Corporation is a medical technology company focused on advanced energy devices for surgical and aesthetic procedures. Its main product is the Renuvion system, which combines helium plasma with radiofrequency energy for use in procedures covered by applicable regulatory clearances. The company also supplies electrosurgical generators and related products, including through its original equipment manufacturing business. Apyx Medical was formerly known as Bovie Medical Corporation and adopted its current name in 2018.
See Also
- Five stocks we like better than Apyx Medical
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.
